All In Biotech

Drug Trial Radar · NCT05397938

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

A Randomized, Double-blind, Double-dummy, Positive-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

Last checked: Nov 19, 2026Latest source record: May 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

231

Planned (sponsor's estimate)

Start

Jun 15, 2022

Primary completion

Jul 1, 2022

Study completion Jun 1, 2023

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
May 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, double-dummy, positive-controlled phase II interventional study designed to evaluate the efficacy and safety of JMT103 in the treatment of glucocorticoid induced osteoporosis patients. Patients will be enrolled and randomized to 3 treatment groups, JMT103 60 mg group (and alendronate sodium tablet placebo), JMT103 90 mg group (and alendronate sodium tablet placebo), and alendronate sodium 70 mg active comparator group (and JMT103 placebo). The primary outcome measure is percent change from baseline in lumbar bone mineral density (BMD) at 12 months of treatment. Besides, percent change of lumbar BMD at 6 months, percent change of total hip and femoral neck BMD at 12 months, and the incidence of new fracture at 12 months will be evaluated. Biomarkers of s-CTX and PINP, PK evaluation of JMT103 serum drug concentration, immunogenicity evaluation of ADA and Nab, and adverse events will be also collected.

Conditions

  • Glucocorticoid Induced Osteoporosis

Interventions

  • JMT103Drug

    JMT103, subcutaneous injection, once every 6 months (Q6M)

  • Alendronate sodiumDrug

    Alendronate sodium tablet, once every week (QW)

  • JMT103 placeboDrug

    JMT103 placebo, subcutaneous injection, once every 6 months (Q6M)

  • Alendronate sodium placeboDrug

    Alendronate sodium tablet placebo, once every week (QW)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change rate of lumbar bone mineral density (BMD) from baseline at 12 monthsTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.